The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production
Bradda Head Lithium exceeds targets, secures US$3 million royalty and moves closer to productionView Video
IntelliAM aiming for significant growth with £5 million Aquis IPO
IntelliAM aiming for significant growth with £5 million Aquis IPOView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.94
Bid: 93.35
Ask: 93.36
Change: -0.13 (-0.143%)
Spread: 0.01 (0.011%)
Open: 91.24
High: 91.56
Low: 90.53
Prev. Close: 90.23
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Drugs group Sanofi makes Olympic jump in rebrand bid

Wed, 10th Jan 2024 06:00

LONDON, Jan 10 (Reuters) - Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker's conservative image.

The 2024 Games has gained other new partners from the host nation France, including luxury goods giant LVMH and supermarket group Carrefour.

Sanofi, which some estimate is spending tens of millions of euros on the Paris Games, says it has sometimes struggled to convince prospective young data managers and data scientists that a pharmaceuticals company is a "cool" place to work.

"We're using the Olympics to show that we are," said Josep Catlla, head of corporate affairs at Sanofi, which is also supporting popular French breakdancer Dany Dann.

The median age of Olympics viewers is rising, data firms have said, and the International Olympic Committee has been trying to drum up Gen Z and Millennial interest through social media campaigns as younger audiences move away from TV, and by introducing newer sports such as breakdancing and skateboarding.

Sanofi is financially supporting 14 individuals in Paris, including British Paralympic swimmer Ellie Challis, in a team comprising an equal number of men and women, and an equal number of Olympic and Paralympic athletes.

"We're playing into the diversity aspect," Catlla said.

Sanofi is also bringing more than 8,000 employees to the Games as volunteers or through internal rewards programmes.

It declined to give details of how much it is spending, saying it is "putting as much money back into our employees as we have paid to the games organizer".

Olympic sponsorship fees alone are between 80 million euros ($87.5 million) and 150 million euros, French media reports have said.

Nick Blenkarne, head of strategy at branding agency Imagination in London, said Sanofi is likely to be looking at its "expensive" sponsorship through several lenses.

These include how it could change the way consumers perceive the company, how it could attract business customers through hospitality programmes, and how it could widen its appeal.

"Positioning yourself as an organisation that wants to do good in the world is always going to be good for attracting new talent," said Blenkarne, whose firm has worked with Samsung and Hyundai at previous Olympic Games.

"Big events like the Olympics and the World Cup are proven to move the needle when it comes to brand perception," he added, noting that brands like Cisco and Visa have also been unlikely, but long-time, Olympic sponsors.

'EXCEPTION'

Catlla said Sanofi, which is one of the biggest makers of vaccines and anti-inflammation treatments and normally sponsors events relating to diseases or patient communities, has made an "exception" for the Olympics partly because they are in Paris.

"We're not in sport and culture or music or other things consumer goods companies do," he added.

The Olympic Games have traditionally seen one-off sponsors from host nations that are not part of the sports or consumer industries. Partners of the Tokyo 2020 Olympics included firms such as Tokyo Gas, Japan Airlines, Nomura and Tanaka Holdings.

Sanofi did not comment when asked whether the French government had suggested it sponsor the Paris Olympics

It remains to see whether Sanofi's sponsorship will move the dial for investor perceptions, after several years of mixed financial results.

"Maybe (the Olympics) is another opportunity to change minds on the company's innovation engine," said Terence McManus, a fund manager with a focus on healthcare at Switzerland's Bellevue Asset Management, which is a Sanofi shareholder.

In October, Sanofi abandoned its 2025 profit target under a plan to list its consumer healthcare business and spend more on testing innovative drugs, wiping 20 billion euros ($22 billion) off its market value.

Sanofi CEO Paul Hudson, who joined four years ago with a mandate to turn the company around, has faced setbacks including the failure of breast cancer pill amcenestrant and losing out in the race for a COVID-19 vaccine.

"I think this (the Olympics) is maybe part of a wider cultural change that the new management team has been at the head of since various members joined between 2019 and now," said Tom Lemaigre, European equities portfolio manager at Sanofi investor Janus Henderson.

"I don't know how sponsoring the Olympics can be seen as a force for bad. They're about unity and competition -- people performing at the highest level."

Lemaigre noted that to the general public and potential employees there could be "a kind of cachet", but "sponsoring a big event like this in and of itself isn't going to change an investor's perception on the company." ($1 = 0.9140 euros) (Reporting by Richa Naidu and Ludwig Berger. Additional reporting by Helen Reid; Editing by Matt Scuffham and Alexander Smith)

More News
24 Jun 2022 09:51

Sanofi, GSK variant-specific COVID shot found effective against Omicron

PARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

Read more
13 Jun 2022 09:09

Sanofi says next-gen COVID booster shot has potential against main variants

PARIS, June 13 (Reuters) - French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.

Read more
10 Jun 2022 09:33

GSK closer to cracking elusive vaccine for common respiratory virus

LONDON, June 10 (Reuters) - GSK aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults.

Read more
30 May 2022 17:34

European shares rise as China growth hopes boost luxury, tech stocks

May 30 (Reuters) - European shares touched their highest level in almost a month on Monday, with optimism buoyed by China's easing of COVID-19 restrictions and adding of new stimulus.

Read more
25 May 2022 11:03

French health body backs new COVID vaccine booster campaign for this autumn

PARIS, May 25 (Reuters) - France's Haute Autorite de Sante (HAS) health authority recommended preparing for a new vaccination campaign this autumn to give people aged 65 and older, and those with special health risks or conditions, access to a COVID-19 "booster" jab.

Read more
28 Apr 2022 16:17

Strong earnings spur rally across European stocks

April 28 (Reuters) - European shares moved further off six-week lows hit last session as forecast-beating results from companies including energy major TotalEnergies and automaker Volvo Car helped set aside worries about slowing global economic growth.

Read more
30 Mar 2022 09:01

What to own in uncertain times

WHAT TO OWN IN UNCERTAIN TIMES (0859 GMT)

Read more
17 Mar 2022 13:56

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert on Thursday said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and the start of July, potentially paving the way for approval this summer.

Read more
17 Mar 2022 13:34

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and July this year, potentially paving the way for a decision by the summer.

Read more
14 Mar 2022 10:18

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Sanofi's shares slid 5% on Monday after a drug candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker's drug development prowess.

Read more
14 Mar 2022 09:11

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial.

Read more
23 Feb 2022 15:31

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 12:44

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 10:22

Healthcare companies Sanofi and GSK to seek COVID-19 vaccine regulatory approval

PARIS, Feb 23 (Reuters) - Healthcare companies Sanofi and GSK said they intend to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Read more
18 Feb 2022 09:00

GSK pauses trial of respiratory virus vaccine in pregnant women

Feb 18 (Reuters) - GSK has paused a late-stage trial of its vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.